Protective effect of oleuropein on ketamine-induced cardiotoxicity in rats.
Animals
Anti-Inflammatory Agents
/ pharmacology
Antioxidants
/ pharmacology
Cardiotoxicity
Disease Models, Animal
Heart Diseases
/ chemically induced
Inflammation Mediators
/ metabolism
Iridoid Glucosides
/ pharmacology
Ketamine
Male
Myocytes, Cardiac
/ drug effects
Oxidative Stress
/ drug effects
Rats, Wistar
Signal Transduction
Cardiotoxicity
Ketamine
Oleuropein
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
21
11
2019
accepted:
08
04
2020
pubmed:
10
5
2020
medline:
29
7
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
The antioxidant and cardioprotective effects of oleuropein have been reported in several studies; however, its effect on ketamine cardiotoxicity has not been known yet. The aim of this study was to investigate the effects of oleuropein in ketamine-induced cardiotoxicity model in rats. A total of 28 male Wistar Albino rats were included in the study and they were randomly divided into four groups, each having seven rats. Group 1 (control): rats were given 1 mL of DMSO by oral gavage method for 7 days. Group 2 (ketamine): on the seventh day of the study, 60 mg/kg ketamine was administered intraperitoneally. Then, 60 mg/kg ketamine was administered intraperitoneally every 10 min for 3 h. Group 3 (oleuropein): rats were given 200 mg/kg/day oleuropein by oral gavage method for 7 days. Group 4 (oleuropein + ketamine): rats were given 1 × 200 mg/kg oleuropein by oral gavage method for 7 days. Furthermore, 60 mg/kg ketamine was administered intraperitoneally on the seventh day of the experiment. Then, 60 mg/kg ketamine was administered intraperitoneally every 10 min for 3 h. Serum cardiac marker (TnI, CK-MB and CK) levels were measured. Histopathological analysis was performed on a portion of the cardiac tissue. Cardiac tissue oxidative stress and antioxidant markers (MDA, GSH, GSH.Px and CAT), TNF-α, IL-6, NF-κB, COX-2 and Nrf-2 gene expressions, and protein conversion levels of related genes were determined. Data obtained showed that ketamine administration increased MDA (p < 0.001), TNF-α (p < 0.01), IL-6 (p < 0.01), COX-2 (p < 0.001) and NF-κB (p < 0.001) levels, as well as serum TnI (p < 0.001), CK-MB (p < 0.001) and CK (p < 0.01) levels whereas decreased GSH (p < 0.05) and Nrf-2 (p < 0.05) levels, as well as GSH-Px (p < 0.001) and CAT (p < 0.05) enzyme activities. Oleuropein administration was observed to decrease MDA, TNF-α, IL-6, COX-2, NF-κB, TnI, CK-MB and CK levels close to the control group and to increase GSH levels and GSH-Px and CAT enzyme activities close to the control group. This study showed that oleuropein administration reversed the increased oxidative stress and inflammation as a result of the use of ketamine and had protective effects on the heart.
Identifiants
pubmed: 32383030
doi: 10.1007/s00210-020-01870-w
pii: 10.1007/s00210-020-01870-w
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antioxidants
0
Inflammation Mediators
0
Iridoid Glucosides
0
oleuropein
2O4553545L
Ketamine
690G0D6V8H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM